Psychopharmacology

Roger S. McIntyre, MD, FRCPC, shares how FDA approval of Caplyta will benefit patients with major depressive disorder

Discover how combining transcranial magnetic stimulation and ketamine therapy revolutionizes treatment for complex conditions like depression and pain.

Discover the latest insights on ADHD diagnosis and treatment, including new DSM-5 criteria and effective therapeutic strategies for diverse patient needs.

Maciej Wieczorek, MD, discusses CPL'36, a new PDA101 inhibitor with a novel mechanism of action for treatment of schizophrenia.

American psychiatry reexamines its roots in psychopathology, challenging DSM's validity and advocating for a return to understanding mental illness.

New research reveals how Candida albicans in the gut microbiome influences alcohol consumption and aversion, offering insights for treating alcohol use disorder.

Explore the intersection of psychotherapy and pharmacology in treating mood disorders, emphasizing personalized approaches for optimal patient outcomes.

Tony Tamburello, MD, discusses advancements in correctional psychiatry, emphasizing ethical care, complex patient needs, and the role of technology in treatment.

A recent study reveals that the choice of initial antipsychotic significantly impacts long-term weight gain, highlighting the complexity of treatment outcomes.

A reproductive psychiatrist discusses the implications of recent FDA announcements on medication use during pregnancy, emphasizing the importance of mental health for mothers and babies.

Explore the complexities of aripiprazole in bipolar disorder treatment, including its efficacy and proper prescribing practices.

New data indicates safety of seltorexant and its pharmacokinetics in treating adolescent depression, supporting its potential as an effective adjunct therapy.

Anebulo Pharmaceuticals initiates a phase 1 trial for selonabant, targeting acute cannabis toxicity in children with promising IV treatment potential.

Explore the challenges and strategies of deprescribing in geriatric psychiatry to enhance patient safety and reduce polypharmacy risks.

Mass shootings are often misattributed to mental illness, overshadowing the real issues of grievance, radicalization, and access to weapons.

Esketamine nasal spray shows significant improvement in emotional blunting for treatment-resistant depression, offering hope for affected patients.

A groundbreaking trial reveals ANK3 as a potential genetic predictor for liafensine's effectiveness in treating resistant depression.

Effective psychiatric training empowers residents to take ownership of patient care, fostering confidence and critical thinking through real-world decision-making.

Combining cognitive behavioral therapy with medication enhances ADHD treatment in adults, showing significant benefits within 3 months.

Discover how blarcamesine, a novel therapy for Alzheimer disease, shows promise in preventing cognitive decline and enhancing patient quality of life.

Simplistic explanations and convenient scapegoats belie the complexity of mass shootings.

It is time to redefine treatment resistance, a definition in which we emphasize comprehensive evaluations and personalized approaches for better patient outcomes.

Thomas Priolo, MD, offers essential strategies for supporting students' mental health during the college transition, emphasizing proactive communication and telehealth options.

Psychiatrists confront the challenge of treatment-resistant depression, balancing honesty and compassion while redefining realistic recovery goals for patients.

Cognition Therapeutics advances zervimesine phase 2 trial, exploring its potential to slow cognitive decline in Alzheimer disease patients.